882272-97-1Relevant articles and documents
HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES
-
Paragraph 00246-00247, (2021/04/17)
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).
COMPOUNDS USEFUL AS KINASE INHIBITORS
-
Paragraph 385-386, (2021/09/17)
Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 0132, (2018/09/16)
Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.
